Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The EU has bought 30,000 doses of the medicine for about 63 million euros from Gilead, and Finland is also getting medicine from this quota. The Ministry of Social Affairs and Health does not say how much medicine has been purchased.
“However, the remdesivirvir that prepares Gilead will not be the only remdesivir. Egypt and India, for example, will have production in the future. ”
The project will continue during the epidemic
The Solidarity research project will not end until the epidemic ends. If the drug is found to be useful, the research project will change so that all patients receive remdesivir.
“In the future, we will probably look at some receiving remdesivir and some in combination with remdesivir and interferon. The theoretical background is that it could help. Interferon activates natural killer defense cells, making it harder for viruses to multiply. ”
The text continues below
"I can't judge whether remdesivirir is more likely to help alone or in combination, but it makes sense to try both options in a randomized setting."
According to Tikkinen, there are, of course, other interesting drugs that are being considered by the WHO pharmacological team.
Tikkinen estimates that remdesivir will not be dramatically good or dramatically harmful in the treatment of coronavirus infection. The main disadvantage has been the increase in the liver values ??of the patients.
Solidarity is already well under way.
“In a few weeks, we may know if remdesivir is really useful or not. If it is useful, it will become standard treatment in those countries that can afford it and can buy it. ”
Coronary patients even younger
According to Tikkinen, patients who came to hospital during the second wave in Finland have been even younger, aged 20–40. The disease can be severe.
“They have pneumonia and need extra oxygen. They will be tested on Remdesivir for 10 days or until they get home; many of the young people have returned home in less than 10 days (even those who do not receive remdesiviir), ”says Tikkinen.
Remdesivir is expected to be useful in the pneumonia phase because it is thought to prevent the virus from multiplying in the body. If the patient is receiving intensive care, remdesivir is probably no longer helpful.
“Dexamethasone, an old and inexpensive cortisone, would instead seem to help those in intensive care; the benefit has been demonstrated in a reliable British Recovery study. The medicine helps in a situation where the body's inflammatory reaction goes so fast that it is life-threatening. ”
In previous studies, remdesivirvir accelerated healing
There are two important but too small studies of remdesivir. The first study, the results of which have been published in The Lancet , was conducted in Wuhan, China, and involved about 240 coronary patients. The drug did not reduce mortality from coronavirus disease.
“Those who received remdesivir improved in 21 days and those who received placebo in 23 days, but the difference is not statistically significant,” says Tikkinen.
The text continues below
Another study of remdesivirir was done in the United States, and it was estimated that the drug would speed recovery in about four days in those who improved, ”says Tikkinen.
The results of the study have been published in The New England Journal of Medicine .
After that, the United States reserved up to 90 percent of drug production in August-September.
The drug license came off quickly
After the study, the drug also quickly received marketing authorization, first in the United States and then in Europe.
“The European Commission, recommended by the (European Medicines Agency) EMA, I think too quickly granted a provisional marketing authorization for the medicine, based on this four-day acceleration of recovery that had been observed in only one study. This may have been due in part to the fact that Americans bought almost the entire stock of remdesivir - they had to give permission to get the drug to Europe as well. Non-medical reasons weigh a lot in today's medicine, ”says Tikkinen.
Seura Article:
Remdesivir is the most promising coronary drug so far and is being studied in Finland as well - The drug may accelerate the recovery of a coronary patient in hospital
According to experts, remdesivir is the most promising corona drug at the moment, but not a panacea. "The potential benefits will not be dramatically large," says Kari Tikkinen, the national lead researcher for the Solidarity project.
The medicine Remdesivir is currently in research use in coronary patients in some hospitals in Finland. Finland is participating in the Solidarity study coordinated by the World Health Organization, which tests various drugs and now especially the use of remdesivir in the treatment of coronavirus patients.
“Our goal is to prevent coronary patients who have been hospitalized with remdesivir come to treatment. The drug is administered intravenously once a day, ”says Professor Kari Tikkinen , Solidarity's national chief researcher .
According to Tikkinen, HUS, Oys, Tays and Kys are involved in the study. TYKS, on the other hand, is not involved. In addition to the university hospitals, six other hospitals are involved, such as Kanta-Häme Central Hospital and Satasaira Hospital in Pori.
The project previously found hydroxychloroquine, which Trump praises as a miracle drug, to be useless and even harmful in the treatment of coronavirus disease, so the drug has been dropped from the Solidarity study.
Only those who are willing will be drawn
Only adult coronavirus patients who are willing to be treated and who are being asked exactly what is involved can participate in the study of remdesivir. Internationally, about 8,000 patients are included in the study, and five patients have been recruited from Finland in the last two weeks.
Lue lisää
Patients are divided into two groups by random sampling (computer lottery): one receives standard care and the other, in addition to standard care, remdesivir. Both the patient and the doctors treating him know whether the patient is receiving remdesivir.
Solidarity is the only study in the world to investigate the suitability of remdesivir for the treatment of coronavirus infection. The American company Gilead Sciences, which makes the drug, does not give the drug in other randomized trials comparing it to standard care.
“The company sells the medicine for use, even though there is no complete certainty about the benefits,” says Tikkinen.
He finds this problematic, as medical treatment should always be based on reliable scientific evidence, not on commercial benefit or preliminary estimates. The drug costs thousands of euros per patient.
According to Tikkinen, there are three main questions in the Solidarity study: Does the drug prevent coronary deaths? Does it prevent you from getting into the power department? Does it have any serious side effects?
The text continues below
"These are all things that are relevant to the patient and for which there are no proper answer
https://twitter.com/karitikkinen/status/1294646959727411202?s=21
Both are still being trialed individually